See more : Sagalio Energy Limited (SAN.AX) Income Statement Analysis – Financial Results
Complete financial analysis of TerrAscend Corp. (TRSSF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of TerrAscend Corp., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Sigma Labs, Inc. (SASI) Income Statement Analysis – Financial Results
- Revelyst, Inc. (GEAR) Income Statement Analysis – Financial Results
- Delignit AG (DLX.DE) Income Statement Analysis – Financial Results
- CIAN Agro Industries & Infrastructure Limited (CIANAGRO.BO) Income Statement Analysis – Financial Results
- NZX Limited (NZSTF) Income Statement Analysis – Financial Results
TerrAscend Corp. (TRSSF)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.terrascend.com
About TerrAscend Corp.
TerrAscend Corp. cultivates, processes, and sells medical and adult use cannabis in Canada and the United States. It produces and distributes hemp-derived wellness products to retail locations; and manufactures cannabis infused artisan edibles. The company also operates three retail dispensaries under the Apothecarium brand name in California and Pennsylvania. In addition, it owns various synergistic under Gage Cannabis, Ilera Healthcare, Kind Tree, Prism, State Flower, Valhalla Confections, and Arise Bioscience Inc. brands. As of July 26, 2022, the company operated 27 dispensaries, including 3 Cookies dispensaries in Michigan and 1 in Toronto. TerrAscend Corp. was incorporated in 2017 and is headquartered in Mississauga, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 317.33M | 322.64M | 243.49M | 198.32M | 84.87M | 6.83M | 0.00 | 0.00 |
| Cost of Revenue | 157.63M | 203.07M | 109.38M | 171.98M | 87.52M | 10.17M | 381.32K | 0.00 |
| Gross Profit | 159.70M | 119.57M | 134.11M | 26.34M | -2.65M | -3.34M | -381.32K | 0.00 |
| Gross Profit Ratio | 50.33% | 37.06% | 55.08% | 13.28% | -3.12% | -48.96% | 0.00% | 0.00% |
| Research & Development | 0.00 | 0.00 | 0.00 | 426.00K | 709.00K | 141.00K | 0.00 | 0.00 |
| General & Administrative | 100.35M | 101.22M | 71.85M | 57.01M | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 9.66M | 10.32M | 1.86M | 1.67M | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 110.01M | 150.48M | 94.16M | 75.17M | 61.68M | 24.67M | 6.27M | 866.94K |
| Other Expenses | 72.69M | 206.00K | 230.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 182.69M | 150.48M | 94.16M | 75.60M | 62.39M | 24.81M | 6.27M | 866.94K |
| Cost & Expenses | 340.32M | 353.55M | 203.54M | 247.58M | 149.91M | 34.98M | 6.66M | 866.94K |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 640.18K | 36.28K | 9.00 |
| Interest Expense | 35.11M | 39.06M | 24.99M | 7.03M | 4.09M | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 22.70M | 32.03M | 17.38M | 16.57M | 7.32M | 921.00K | 244.08K | 0.00 |
| EBITDA | -1.03M | -320.94M | 104.54M | -96.45M | -204.22M | -20.52M | -6.56M | -866.94K |
| EBITDA Ratio | -0.32% | 0.35% | 23.54% | -16.48% | -68.01% | -398.97% | 0.00% | 0.00% |
| Operating Income | -23.00M | -30.91M | 39.95M | -49.26M | -65.04M | -28.16M | -6.66M | -866.94K |
| Operating Income Ratio | -7.25% | -9.58% | 16.41% | -24.84% | -76.63% | -412.47% | 0.00% | 0.00% |
| Total Other Income/Expenses | -35.84M | -279.28M | 15.88M | -77.21M | -152.29M | 6.72M | -149.23K | -244.00 |
| Income Before Tax | -58.83M | -403.82M | 55.83M | -126.47M | -217.33M | -21.44M | -6.81M | -867.18K |
| Income Before Tax Ratio | -18.54% | -125.16% | 22.93% | -63.77% | -256.08% | -314.09% | 0.00% | 0.00% |
| Income Tax Expense | 23.45M | -14.04M | 36.20M | 27.87M | 1.62M | 704.00K | -3.00 | 0.00 |
| Net Income | -91.10M | -429.49M | 3.90M | -155.12M | -215.79M | -22.03M | -6.81M | -867.18K |
| Net Income Ratio | -28.71% | -133.12% | 1.60% | -78.22% | -254.26% | -322.71% | 0.00% | 0.00% |
| EPS | -0.33 | -1.76 | 0.02 | -1.04 | -2.17 | -0.24 | -0.18 | -0.03 |
| EPS Diluted | -0.33 | -1.76 | 0.02 | -1.04 | -2.17 | -0.24 | -0.18 | -0.03 |
| Weighted Avg Shares Out | 279.29M | 244.35M | 181.06M | 149.74M | 99.59M | 90.98M | 37.63M | 29.24M |
| Weighted Avg Shares Out (Dil) | 279.29M | 244.35M | 208.71M | 149.74M | 99.59M | 90.98M | 37.63M | 29.24M |
2 Top Marijuana Stocks To Buy For Cannabis Investing?
Cantor Fitzgerald discontinues cannabis stock coverage with analyst departure
Looking For Marijuana Stocks To Buy Before May?3 To Watch Under $2
Cannabis Stocks To Buy In April? 2 To Watch This Week
2 Marijuana Stocks For Cannabis Investors 2023
This Will Be a Big Test for the Cannabis Industry
2 Marijuana Stocks To Buy This April 2023?
Finding The Long-Term Winners In The Cannabis Sector
High & Dry: Banking crisis to further choke funding for cannabis sector
TerrAscend retains ‘Buy' rating from Canaccord with reduced price target following 4Q results
Source: https://incomestatements.info
Category: Stock Reports